基因组融合断点用于儿童急性淋巴细胞白血病DNA水平可测量残留病监测
该研究在403例已知或疑似融合的儿童ALL患者中,采用短读长捕获测序和开源流程,97%的病例成功识别患者特异性基因组融合断点。基于GFB的qPCR或ddPCR MRD检测特异性高、检测阈值更低,敏感性优于IG/TCR方法;在104例纵向监测中,非BCR::ABL ALL两法总体一致性极好,但在ETV6::RUNX1和MEF2D重排ALL中GFB-MRD更具信息价值。
要点
- 短读长捕获测序可在97%的儿童ALL融合阳性病例中识别患者特异性GFB。
- GFB-MRD检测特异性高、阈值更低,敏感性优于IG/TCR方法。
- ETV6::RUNX1和MEF2D重排ALL中GFB-MRD尤具信息价值。
核心结论
- 基因组融合断点可作为稳健、可临床实施的MRD标志物,但选择标志物和解读结果需考虑亚型特异性生物学。
研究设计与样本
- 在403例已知或疑似融合的儿童ALL患者中,采用短读长、基于捕获的下一代测序策略结合开源流程识别GFB。
- 在104例涵盖多种儿童ALL融合亚型的患者中进行纵向监测,比较GFB-MRD与IG/TCR-MRD方法。
主要发现
- 在97%的病例中识别出患者特异性GFB。
- GFB-MRD检测(qPCR或ddPCR)显示极高特异性,检测阈值更低,敏感性优于IG/TCR方法。
- 非BCR::ABL ALL中两法总体一致性极好,但存在融合依赖的差异。
- ETV6::RUNX1重排ALL中IG/TCR追踪常因持续重排而不理想,MEF2D重排ALL中因缺乏VDJ重排而不可靠,GFB-MRD在这些亚型中尤其有信息价值。
临床怎么用
- GFB可作为儿童ALL MRD监测的替代标志物,尤其适用于IG/TCR追踪不可靠的亚型。
- 选择GFB标志物和解读MRD结果时需考虑ALL亚型特异性生物学。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Measurable residual disease (MRD) is a key prognostic factor in pediatric acute lymphoblastic leukemia (ALL), but current gold-standard methods based on immunoglobulin/T-cell receptor (IG/TCR) rearrangements are complex and not informative in a subset of patients. Genomic breakpoints of oncogenic fusions (GFBs) are stable, biologically grounded markers that may overcome these limitations and improve MRD assessment. In a cohort of 403 patients with known or suspected fusions, a short-read, capture-based next-generation sequencing strategy coupled with an open-source pipeline identified patient-specific GFBs in 97% of cases. GFB-based MRD assays implemented by qPCR or ddPCR showed very high specificity and allowed lower detection thresholds, resulting in improved sensitivity relative to IG/TCR-based assays. Longitudinal monitoring in 104 patients across multiple pediatric ALL fusion subtypes demonstrated excellent overall concordance between methods in non-BCR::ABL ALL, while revealing fusion-dependent differences. GFB-based MRD was particularly informative in ETV6::RUNX1- and MEF2D-rearranged ALL, where IG/TCR tracking is frequently suboptimal or unreliable due to ongoing rearrangements or the absence of VDJ recombination, respectively. Altogether, this large-scale study establishes GFBs as robust, clinically implementable MRD markers and supports their integration into clinical strategies, provided that subtype-specific biology is considered when selecting markers and interpreting results.
引用
- Houtman AH, Arfeuille C, Strullu M, et al. Genomic fusion breakpoints for DNA-based measurable residual disease monitoring in pediatric acute lymphoblastic leukemia. Leukemia. 2026. PMID: 42014859. doi:10.1038/s41375-026-02958-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。